Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Einstein on Treatment Approaches in Early Oligometastatic Prostate Cancer

June 26th 2019

David J. Einstein, MD, instructor of medicine, Harvard Medical School, attending physician, Beth Israel Deaconess Medical Center, discusses treatment approaches for patients with early evidence of oligometastatic prostate cancer.

Dr. Lee on the Role of Darolutamide in M0CRPC

June 25th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the role of darolutamide in nonmetastatic castration-resistant prostate cancer (M0CRPC).

Enzalutamide Improves rPFS Regardless of PSA Levels in Hormone-Sensitive Prostate Cancer

June 25th 2019

Enzalutamide in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer demonstrated significantly improved radiographic progression-free survival versus placebo plus ADT, regardless of baseline prostate-specific antigen levels, according to expanded findings from the ARCHES study.

Pembrolizumab Plus Olaparib Shows Potential in Heavily Pretreated mCRPC

June 24th 2019

Evan Y. Yu, MD, discusses updated data from cohort A of the KEYNOTE-365 trial in patients with metastatic castration-resistant prostate cancer.

Urologists Will Need Training in Immuno-Oncology Adverse Events

June 22nd 2019

As immunotherapy has become increasingly utilized, urologists are more frequently participating in the management of patients who are receiving immunotherapy.

Dr. Yu on Combining Pembrolizumab and Olaparib in mCRPC

June 21st 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combining pembrolizumab and olaparib in metastatic castration-resistant prostate cancer.

Does Immuno-Oncology Therapy Have a Larger Role in the Urology Clinic?

June 21st 2019

The FDA approved indications in urologic cancers for 6 immune checkpoint inhibitors since 2015. That is unquestionably a good thing for patients, but the rise of these agents means that the role of the urologist in cancer care is changing, and some urologists are still on the fence about these agents.

Dr. Quinn on Novel Hormonal Therapies in Prostate Cancer

June 21st 2019

David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the rise of novel hormonal therapies in prostate cancer.

Urologists Must Keep Up With Advances and Stay at the Helm

June 20th 2019

Over the past 5 years, the need for urologists to continue to be the leaders— the quarterbacks—in the diagnosis and management of prostate cancer has often been discussed. History will attest to urologists' success in leading this charge.

Urology Austin Innovates to Deliver High-Quality Care

June 20th 2019

The decision to expand a practice comes with great financial cost and administrative effort. For Urology Austin, however, the benefits for their patients have outweighed the challenges of such growth.

Dr. Mouw on the Role of Radiation Therapy in Prostate Cancer

June 20th 2019

Kent W. Mouw, MD, PhD, co-director, Bladder Cancer Center, assistant professor, Radiation Oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of radiation therapy in prostate cancer.

Dr. Lee on Inclusion Criteria of the ARAMIS, SPARTAN, and PROSPER Trials in M0CRPC

June 20th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses inclusion criteria of the phase III ARAMIS, SPARTAN, and PROSPER trials in nonmetastatic castration-resistant prostate cancer (M0CRPC).

PSMA Emerges as Versatile Target in Prostate Cancer and Beyond

June 19th 2019

Named the medical invention of the Year by TIME magazine at the turn of the millennium, positron emission tomography/computed tomography has changed the landscape of cancer diagnosis, facilitating earlier detection and more accurate staging of a range of tumor types.

Dr. Einstein on Novel Imaging Tools in Prostate Cancer

June 19th 2019

David J. Einstein, MD, genitourinary medical oncologist, Beth Israel Deaconess Medical Center, discusses novel imaging tools used in prostate cancer.

Dr. McGregor on Guidelines Regarding ADT-Associated Cardiac AEs in Prostate Cancer

June 19th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses guidelines regarding androgen deprivation therapy (ADT)-associated cardiac adverse events (AEs) in prostate cancer.

Dr. Caffo Discusses Enzalutamide/Docetaxel Combination in Frontline mCRPC

June 17th 2019

Orazio Caffo, MD, director of medical oncology at the Santa Chiara Hospital in Trento, Italy, discusses enzalutamide plus docetaxel combination for the frontline treatment of metastatic castration-resistant prostate cancer.

Immune System Agents May Move Into Earlier Settings in GU Cancers

June 13th 2019

Over the past 5 years, medical oncologists have witnessed the revolutionary impact of immunotherapy on patients with advanced urologic malignancies. Over the next 5 years, these therapies likely will similarly transform urologic surgical care.

SM-88 Shows Efficacy in Pancreatic, Prostate Cancers

June 13th 2019

Having a late-stage treatment for pancreatic cancer that avoids many of the adverse events associated with chemotherapy would be a boon for patients.

Dr. Fizazi Discusses Updated Data With Darolutamide in CRPC

June 13th 2019

Karim Fizazi, MD, PhD, head, Department of Cancer Medicine, Gustave Roussy Cancer Center, Villejuif, France, discusses updated data with darolutamide in castration-resistant prostate cancer.

Dr. Choudhury on the Importance of Volume Status in Metastatic Prostate Cancer

June 12th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the importance of volume status in prostate cancer.